Shares of Fulgent Genetics FLGT moved higher by 24.0% in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were up 15400.00% year over year to $6.20, which beat the estimate of $4.05.
Revenue of $294,978,000 rose by 3417.09% year over year, which beat the estimate of $199,440,000.
Guidance
Fulgent Genetics Sees FY21 EPS ~$12.50 Vs. $11.55 Est., Sales ~$800M Vs. $600.24M Est.
Details Of The Call
Date: Mar 04, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/jf6vsajc
Technicals
52-week high: $189.89
52-week low: $6.70
Price action over last quarter: Up 246.36%
Company Profile
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to a disease and enhanced disease treatment and prognosis.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.